Synergistic Effects of Nuclear Transcription Factor NF-kB Inhibitors and Anti-Neoplastic Agents

Abstract

The present invention provides methods of inhibiting metastasis of a tumor and methods of treating a tumor using a combination of an inhibitor of the activation of nuclear factor NF-κB and a cancer chemotherapeutic agent. In one embodiment of the present invention, combination of curcumin and paclitaxel (taxol) can be used to treat and inhibit metastasis of breast tumor.

1 - 24 . (canceled)  
   
   
       25 . A method treating a chemoresistant cancer in a subject, comprising the steps of: 
 a) administering to said subject a curcuminoid, and    b) administering to said subject one or more chemotherapeutic agent, wherein the chemoresistant cancer becomes chemosensitive to said one or more chemotherapeutic agents as a result of administration of said curcuminoid.    
   
   
       26 . The method of  claim 25 , wherein said subject is a human.  
   
   
       27 . The method of  claim 25 , wherein a cell of the cancer overexpress NF-κB.  
   
   
       28 . The method of  claim 25 , wherein the cancer is selected from the group consisting of breast cancer, prostate cancer, melanoma, pancreatic cancer, colon cancer, and multiple myeloma  
   
   
       29 . The method of  claim 25 , wherein said one or more chemotherapeutic agents are selected from the group consisting of paclitaxel, gemcitabin, 5-flurouracil, etoposide, cispaltin, campothecin, vincristine and doxorubicin.  
   
   
       30 . The method of  claim 25 , wherein said curcuminoid is administered orally.  
   
   
       31 . The method of  claim 25 , wherein said dose of the curcuminoid is from about 10 mg/kg to about 1000 mg/kg.  
   
   
       32 . The method of  claim 28 , wherein the cancer is a multiple myeloma.  
   
   
       33 . The method of  claim 32 , wherein the cells of the multiple myeloma cells are CD138.sup.+plasma cells.  
   
   
       34 . The method of  claim 25 , wherein said one or more cancer chemotherapeutic agents are selected from the group consisting of paclitaxel, gemcitabin, 5-flurouracil, etoposide, cispaltin, campothecin, vincristine and doxorubicin.